Harm reduction

Ophelia Maternal Care

Ophelia is launching a dedicated clinical program for pregnant and postpartum patients with opioid use disorder.

By:
Ophelia team
Pregnant person resting their hands on their belly
Icon of shield with check mark inside
Medically reviewed by
Ophelia team
Last updated on May 05, 2026

Ophelia Maternal Care is here. And it's long overdue.

This Mother's Day, we're announcing something we've been working toward for a long time.

Every six minutes, an American dies of an opioid overdose. For pregnant patients managing opioid use disorder, the stakes are even higher and the access to care even worse. Many pregnant patients with OUD never receive treatment. Not because treatment doesn't exist. Not because the evidence isn't clear. Because the systems in place today weren't built for them.

Today, we're changing that.

We're formally launching Ophelia Maternal Care, a dedicated clinical program for pregnant and postpartum patients managing OUD, built on years of clinical experience, strong outcomes data, and a clear understanding of why this gap has persisted so long.

Pregnant patients with OUD face stigma from providers who don't know how to help, fragmented care that drops them at delivery, and dangerous misinformation telling them to stop their medication. We built Ophelia Maternal Health to address all of it: a specialized clinical team, protocols grounded in ACOG guidelines, and a fully virtual model that removes the access barriers keeping patients from care.

The financial case is just as clear as the clinical one, and it operates on two levels. For all patients, not ust pregnant people, Ophelia's outcomes data, drawn from a broad Medicaid population, shows a 70% reduction in total cost of care while in treatment, a 72% reduction in ED visits, and a 95% reduction in inpatient mental health costs. But the downstream savings matter just as much: when pregnant patients with OUD receive effective treatment, the costs that follow are dramatically different. A single Neonatal Abstinence Syndrome (NAS)-related NICU admission can exceed $50,000. Keeping patients in stable, evidence-based care during pregnancy is both the right clinical decision and what prevents those admissions from happening in the first place. For payors and MCOs managing this population, the return on covered MOUD treatment is significant and measurable.

Sources

Treatment that works is right at your fingertips.

Get started
X